• Mrridula Dangi Narwal Department of Biotechnology , Centre for Biotechnology, M.D. University, Rohtak, Haryana, India.
  • Meenakshi Balhara Department of Biotechnology , Centre for Biotechnology, M.D. University, Rohtak, Haryana, India.
  • Renu Chaudhary Department of Biotechnology , Centre for Biotechnology, M.D. University, Rohtak, Haryana, India.
  • Chhillar Ak Department of Biotechnology , Centre for Biotechnology, M.D. University, Rohtak, Haryana, India.


Scientific and clinical reports globally demonstrated that the opportunistic mycotic infections are at major risk to the human fitness. In past few decades, development of resistance in microbes to existing antifungals, has emphasized on the search of new antimycotic drugs. As a matter of fact "echinocandins" are new categories of broad-spectrum antifungal enlighten a hope in this direction. Echinocandins are bulky lipopeptides that inhibits the production of β-[1,3]-glucan "a major constituent of fungal cell wall" which ultimately leads to the death of fungal pathogens. In vitro as well as in vivo published reports have demonstrated that the echinocandins exhibit fungicidal activity against most Candida spp while fungistatic against Aspergillus spp and exclusively found to be more effective when tested in combination with polyenes/azoles. Present article is an expert views on the recent and historical literature available on the antifungal therapies with accessing their impact on the human health. Emphasis is given on the utility of the echinocandins as potential antifungal agent by discussing recent examples of clinical and laboratory studies including the use of improved proteomics approaches to know a bit more about the interaction of human host and fungal pathogens.

Keywords: Echinocandins, Antifungal, Aspergillus, Candida, Opportunistic, Combination.


1. Frange P, Bougnoux ME, Lanternier F, Neven B, Moshous D, Angebault C, et al. An update on pediatric invasive aspergillosis. Med Mal Infect 2015;45(6):189-98.
2. Taccone FS, Van den Abeele AM, Bulpa P, Misset B, Meersseman W, Cardoso T, et al. Epidemiology of invasive aspergillosis in critically ill patients: Clinical presentation, underlying conditions, and outcomes. Crit Care 2015;19:7.
3. Curbelo J, Galván JM, Aspa J. Updates on Aspergillus, Pneumocystis and other opportunistic pulmonary mycoses. Arch Bronconeumol 2015;51:647-53.
4. Neoh CF, Slavin M, Chen SC, Stewart K, Kong DC. Echinocandins in the treatment of candidaemia and invasive candidiasis: Clinical and economic perspectives. Int J Antimicrob Agents 2014;43:207-14.
5. Lackner M, Tscherner M, Schaller M, Kuchler K, Mair C, Sartori B, et al. Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment. Antimicrob Agents Chemother 2014;58(7):3626-35.
6. Lum KY, Tay ST, Le CF, Lee VS, Sabri NH, Velayuthan RD, et al. Activity of novel synthetic peptides against Candida albicans. Sci Rep 2015;5:9657.
7. De Rosa FG, Corcione S, Filippini C, Raviolo S, Fossati L, Montrucchio C, et al. The effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards. PLoS One 2015;10(5):e0125149.
8. Thakur R, Anand R, Tiwari S, Singh AP, Tiwary BN, Shankar J. Cytokines induce effector T-helper cells during invasive aspergillosis; What we have learned about T-helper cells? Front Microbiol 2015;6:429.
9. Montagna MT, Caggiano G, Lovero G, De Giglio O, Coretti C, Cuna T, et al. Epidemiology of invasive fungal infections in the intensive care unit: Results of a multicenter Italian survey (AURORA project). Infection 2013;41(3):645-53.
10. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004;170(6):621-5.
11. Medeiros CI, Silva DD, Filho GG, Filho AA, Lima EE. Activity anti-c. Tropicalis and effects of the combination of (s)-(-)-citronellal with four antifungal applied in vulvovaginal candidiasis. Int J Pharm Pharm Sci 2016;8(8):347-51.
12. Ruhil S, Balhara M, Dhankhar S, Kumar V, Chhillar AK. Invasive aspergillosis: Adjunctive combination therapy. Mini Rev Med Chem 2012;12(12):1261-72.
13. Fekkar A, Dannaoui E, Meyer I, Imbert S, Brossas JY, Uzunov M, et al. Emergence of echinocandin-resistant Candida spp. In a hospital setting: A consequence of 10 years of increasing use of antifungal therapy? Eur J Clin Microbiol Infect Dis 2014;33(9):1489-96.
14. González de Molina F, Martínez-Alberici Mde L, Ferrer R. Treatment with echinocandins during continuous renal replacement therapy. Crit Care 2014;18(2):218.
15. Stan CD, Tuchilus C, Stan CI. Echinocandins - new antifungal agents. Rev Med Chir Soc Med Nat Iasi 2014;118(2):528-36.
16. Zhang C, Cheng J, Jiang Y, Liu J. Application of caspofungin in China compared with amphotericin B and fluconazole. Ther Clin Risk Manag 2014;10:737-41.
17. Bolard J. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim Biophys Acta 1986;864(3-4):257-304.
18. Steinbach WJ, Juvvadi PR, Fortwendel JR, Rogg LE. Newer combination antifungal therapies for invasive aspergillosis. Med Mycol 2011;49 Suppl 1:S77-81.
19. Prasad R, Shah AH, Rawal MK. Antifungals: Mechanism of action and drug resistance. In: Jose R, Hana S, Maik K, editors. Yeast Membrane Transport. Vol. 892. Switzerland: Springer; 2016. p. 327-49.
20. Morrison VA. Echinocandin antifungals: Review and update. Expert Rev Anti Infect Ther 2006;4(2):325-42.
21. Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm 2006;63(19):1813-20.
22. Pfaller MA, Messer SA, Jones RN, Castabheira M. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: Data from the SENTRY antifungal surveillance program (2010-2012). J Antibiot 2015;68 Suppl 9:556-61.
23. Matsumoto E, Boyken L, Tendolkar S, McDanel J, Castanheira M, Pfaller M, et al. Candidemia surveillance in Iowa: Emergence of echinocandin resistance. Diagn Microbiol Infect Dis 2014;43 Suppl 3:207-14.
24. Pham CD, Iqbal N, Bolden CB, Kuykendall RJ, Harrison LH, Farley MM. Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 2014;44 Suppl 2:96-104.
25. Dudiuk C, Gamarra S, Leonardeli F, Jimenez-Ortigosa C, Vitale RG, Afeltra J, et al. Set of classical PCRs for detection of mutations in Candida glabrata FKS genes linked with echinocandin resistance. J Clin Microbiol 2014;52:2609-14.
26. Walker LA, Gow NA, Munro CA. Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob Agents Chemother 2013;57(1):146-54.
27. Czub J, Baginski M. Modulation of amphotericin B membrane interaction by cholesterol and ergosterol - A molecular dynamics study. J Phys Chem B 2006;110:16743-53.
28. Stone EA, Fung HB, Kirschenbaum HL. Caspofungin: An echinocandin antifungal agent. Clin Ther 2002;24(33):351-77.
29. Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med Mycol 2006;44:69-73.
30. Dennis CG, Greco WR, Brun Y, Youn R, Slocum HK, Bernacki RJ. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox/mouse model of chronic granulomatous disease. Antimicrob Agents Chemother 2006;50:422-7.
31. Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: What are the differences? Clin Microbiol Infect 2008;14 Suppl 4:25-36.
32. Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK. Combination antifungal therapy of murine aspergillosis: Liposomal amphotericin B and micafungin. J Antimicrob Chemother 2003;52:656-62.
33. Wasan KM, Sivak O, Rosland M, Risovic V, Bartlett K. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus. J Pharm Sci 2007;96(7):1737-47.
34. Abidi MZ, Sohail MR, Cummins N, Wilhelm M, Wengenack N, Brumble L, et al. Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: A comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies. Mycoses 2014;57(11):687-98.
35. Olson JA, George A, Constable D, Smith P, Proffitt R, Moore JP. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections. Antimicrob Agents Chemother 2010;54:3884-94.
36. Yilmaz D, Balkan C, Ay Y, Akin M, Karapinar B, Kavakli K. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections. Mycoses 2011;54(3):234-42.
37. Wang JF, Xue Y, Zhu XB, Fan H. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: A meta-analysis of RCTs. Eur J Clin Microbiol Infect Dis 2015;34(4):651-9.
38. Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, et al. Combination antifungal therapy for invasive aspergillosis: A randomized trial. Ann Intern Med 2015;162:81-9.
39. Ogawa T, Matsumoto K, Tsujimoto K, Hishiya N, Yamada Y, Uno K, et al. Chronic invasive sinus and intracerebral aspergillosis controlled by combination therapy with micafungin and a daily dose of 400 mg itraconazole oral solution. J Infect Chemother 2015;21(2):134-7.
40. Kiehl MG, Egerer G, Engelhardt M, Gross B. Empirical caspofungin therapy in clinical practice for suspected invasive fungal disease in adults with acute lymphoblastic leukaemia. Mycoses 2015;58(2):76-81.
41. Kobayashi C, Hanadate T, Niwa T, Hirano Y, Yoshiyasu T, So M, et al. Safety and efficacy of micafungin for prophylaxis against invasive fungal infections in Japanese patients undergoing hematopoietic stem cell transplantation: Results of a post-marketing surveillance study. J Infect Chemother 2015;21(6):438-43.
42. Nandhini SU, Bharathy PJ, Rekha S. Antifungal compounds from marine Streptomyces. Int J Pharm Pharm Sci 2015;7(1):207-9.
43. Bochennek K, Balan A, Müller-Scholden L, Becker M, Farowski F, Müller C, et al. Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease. J Antimicrob Chemother 2015;70(5):1527-30.
44. Rosato A, Catalano A, Carocci A, Carrieri A, Carone A, Caggiano G, et al. In vitro interactions between anidulafungin and nonsteroidal anti-inflammatory drugs on biofilms of Candida spp. Bioorg Med Chem 2016;24(5):1002-5.
45. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993;61(4):1185-93.
46. Pursell K, Verral S, Daraiesh F, Shrestha N, Skariah A, Hasan E, et al. Impaired phagocyte respiratory burst responses to opportunistic fungal pathogens in transplant recipients: In vitro effect of r-metHuG-CSF (filgrastim). Transpl Infect Dis 2003;5:29-37.
47. Masaphy S. A novel echinocandin MIG0310 with anticandida activity from newly isolated Fusarium sp. Strain MS-R1. J Appl Microbiol 2014;116(6):1458-64.
48. Pfaller MA, Rhomberg PR, Messer SA, Castanheira M. In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species. Diagn Microbiol Infect Dis 2015;81(4):259-63.
49. Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, et al. The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans. Antimicrob Agents Chemother 2015;59(2):1341-3.
50. Wiederhold NP, Najvar LK, Matsumoto S, Bocanegra RA, Herrera ML, Wickes BL, et al. Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2015;59(2):2875-81.
51. Nagayoshi Y, Miyazaki T, Minematsu A, Yamauchi S, Takazono T, Nakamura S, et al. Contribution of the Slt2-regulated transcription factors to echinocandin tolerance in Candida glabrata. FEMS Yeast Res 2014;14(7):1128-31.
52. Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-ß-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis 2012;55(8):521-6.
53. Hanson KE, Pfeiffer CD, Lease ED, Balch AH, Zaas AK, Perfect JR, et al. ß-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: A randomized pilot study. PLoS One 2012;7(4):e42282.
54. Bills G, Li Y, Chen L, Yue Q, Niu XM, An Z. New insights into the echinocandins and other fungal non-ribosomal peptides and peptaibiotics. Nat Prod Rep 2014;31(10):1348-75.
55. Gil-Alonso S, Jauregizar N, Cantón E, Eraso E, Quindós G. Comparison of the in vitro activity of echinocandins against Candida albicans, Candida dubliniensis, and Candida africana by time-kill curves. Diagn Microbiol Infect Dis 2015;82(1):57-61.
56. Cangemi G, Barco S, Bandettini R, Castagnola E. Quantification of micafungin in human plasma by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2014;406(6):1795-8.
57. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004;3(12):1154-69.
58. Zieske LR. A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. J Exp Bot 2006;57(9):1501-8.
59. Cagas SE, Jain MR, Li H, Perlin DS. Profiling the Aspergillus fumigatus proteome in response to caspofungin. Antimicrob Agents Chemother 2011;55(1):146-54.
60. da Silva Ferreira ME, Malavazi I, Savoldi M, Brakhage AA, Goldman MH, Kim HS, et al. Transcriptome analysis of Aspergillus fumigatus exposed to voriconazole. Curr Genet 2006;50(1):32-44.
61. Gautam P, Shankar J, Madan T, Sirdeshmukh R, Sundaram CS, Gade WN, et al. Proteomic and transcriptomic analysis of Aspergillus fumigatus on exposure to amphotericin B. Antimicrob Agents Chemother 2008;52(12):4220-7.
62. Hoehamer CF, Cummings ED, Hilliard GM, Rogers PD. Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents. Antimicrob Agents Chemother 2010;54(5):1655-64.
511 Views | 537 Downloads
How to Cite
Narwal, M. D., M. Balhara, R. Chaudhary, and C. Ak. “ECHINOCANDINS VERSUS DATED ANTIFUNGALS IN COMBINATION AGAINST OPPORTUNISTIC MYCOTIC INFECTIONS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 8, Aug. 2017, pp. 54-59, doi:10.22159/ajpcr.2017.v10i8.17186.
Review Article(s)